Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Recordati Snags Japan Rights to BMS’ Myelofibrosis Med Inrebic
Recordati Rare Diseases Japan said on December 18 that it has obtained the rights to manufacture and market Bristol Myers Squibb’s myelofibrosis therapy Inrebic (fedratinib) in Japan, which has been approved domestically but has yet to be launched. The company…
To read the full story
Related Article
- Servier’s Voranigo Skips November Listing; GSK, BMS Drugs Also Absent
November 6, 2025
- GSK’s Blenrep, BMS’s Inrebic Absent from October Listing Roster
October 17, 2025
- Japan Approves MSD’s Airwin/Welireg, J&J Bispecific, and More
June 25, 2025
BUSINESS
- Daiichi Sankyo Taps Ex-Novartis CMO John Tsai as R&D Head
February 24, 2026
- Shionogi to Absorb Torii in April 2027
February 24, 2026
- Sumitomo, Partners Launch Malaria Vaccine Project Targeting Mid-2030s Approval
February 24, 2026
- Oji Takes Stake in LTL Pharma to Tap LLP Expertise
February 24, 2026
- Hisamitsu Buyout Closed, Drug Maker Set to Go Private in May
February 24, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…